Related references
Note: Only part of the references are listed.Current progress in innovative engineered antibodies
William R. Strohl
PROTEIN & CELL (2018)
Insertion of scFv into the hinge domain of full-length IgG1 monoclonal antibody results in tetravalent bispecific molecule with robust properties
Binyam Bezabeh et al.
MABS (2017)
The making of bispecific antibodies
Ulrich Brinkmann et al.
MABS (2017)
Bispecific antibodies
Roland E. Kontermann et al.
DRUG DISCOVERY TODAY (2015)
Alternative molecular formats and therapeutic applications for bispecific antibodies
Christoph Spiess et al.
MOLECULAR IMMUNOLOGY (2015)
Amgen's bispecific antibody puffs across finish line
Cormac Sheridan
NATURE BIOTECHNOLOGY (2015)
Bispecific T-cell engagers for cancer immunotherapy
Amelia M. Huehls et al.
IMMUNOLOGY AND CELL BIOLOGY (2015)
Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cells
Jeffrey C. Kang et al.
MABS (2014)
Bispecific antibodies rise again
Ken Garber
NATURE REVIEWS DRUG DISCOVERY (2014)
Characterization of Therapeutic Antibodies and Related Products
Alain Beck et al.
ANALYTICAL CHEMISTRY (2013)
Knobs-into-holes antibody production in mammalian cell lines reveals that asymmetric afucosylation is sufficient for full antibody-dependent cellular cytotoxicity
Whitney Shatz et al.
MABS (2013)
A series of anti-CEA/anti-DOTA bispecific antibody formats evaluated for pre-targeting: comparison of tumor uptake and blood clearance
Paul J. Yazaki et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2013)
Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition
Rebecca Croasdale et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2012)
World Bispecific Antibody Summit, September 27–28, 2011, Boston, MA
Eugen Dhimolea et al.
mAbs (2012)
Blinatumomab: A historical perspective
Dirk Nagorsen et al.
PHARMACOLOGY & THERAPEUTICS (2012)
Development of Tetravalent, Bispecific CCR5 Antibodies with Antiviral Activity against CCR5 Monoclonal Antibody-Resistant HIV-1 Strains
Juergen Schanzer et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity
Jianying Dong et al.
MABS (2011)
Bispecific digoxigenin-binding antibodies for targeted payload delivery
Silke Metz et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Enhancing Antibody Fc Heterodimer Formation through Electrostatic Steering Effects APPLICATIONS TO BISPECIFIC MOLECULES AND MONOVALENT IgG
Kannan Gunasekaran et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Structural and functional characterization of the trifunctional antibody catumaxomab
Dirk Chelius et al.
MABS (2010)
Engineering of stable bispecific antibodies targeting IL-17A and IL-23
Robert Mabry et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2010)
Bispecific T-Cell Engaging Antibodies for Cancer Therapy
Patrick A. Baeuerle et al.
CANCER RESEARCH (2009)
The Design and Characterization of Oligospecific Antibodies for Simultaneous Targeting of Multiple Disease Mediators
Nazzareno Dimasi et al.
JOURNAL OF MOLECULAR BIOLOGY (2009)
Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTβR
Jennifer S. Michaelson et al.
MABS (2009)
Charge-based analysis of antibodies with engineered cysteines From multiple peaks to a single main peak
Xiaoying (Nancy) Chen et al.
MABS (2009)
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
Jagath R. Junutula et al.
NATURE BIOTECHNOLOGY (2008)
BiTEs: bispecific antibody constructs with unique anti-tumor activity
E Wolf et al.
DRUG DISCOVERY TODAY (2005)
Expression of a bispecific dsFv-dsFv′ antibody fragment in Escherichia coli
A Schmiedl et al.
PROTEIN ENGINEERING (2000)
Share Paper
